A Study of IBI362 9 mg in Chinese Adults With Obesity

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

462

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

June 27, 2025

Study Completion Date

September 19, 2025

Conditions

Obesity

Interventions

DRUG

IBI362

Once-weekly injections of gradually increased doses of IBI362

DRUG

Placebo

Once-weekly injections of volume-matched placebo

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06164873 - A Study of IBI362 9 mg in Chinese Adults With Obesity | Biotech Hunter | Biotech Hunter